Tuesday 10 January | |
Valereum Blockchain PLC | AGM |
Wishbone Gold PLC | AGM |
Wednesday 11 January | |
AB Dynamics PLC | AGM |
Asos PLC | AGM |
Edge Performance VCT PLC | GM re deed of release |
Hurricane Energy PLC | AGM |
Induction Healthcare Group PLC | AGM |
MetalNRG PLC | GM requisitioned to remove chair and CEO from board |
Synthomer PLC | GM re sale of laminates business |
Thursday 12 January | |
JPMorgan Japanese Investment Trust PLC | AGM |
Friday 13 January | |
eEnergy Group PLC | GM re shareholder resolution to adopt the 2022 Accounts |
Monday 16 January | |
4D Pharma PLC | GM re update on administration and suspension of trading |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial
4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.
Read more